Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Cancer Chemother Pharmacol. 2019 Nov;84(5):925-935. doi: 10.1007/s00280-019-03912-4. Epub 2019 Jul 31.
Thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH are key members of the Trx system that is involved in redox regulation and antioxidant defense. In recent years, several researchers have provided information about the roles of the Trx system in cancer development and progression. These reports indicated that many tumor cells express high levels of Trx and TrxR, which can be responsible for drug resistance in tumorigenesis. Inhibition of the Trx system may thus contribute to cancer therapy and improving chemotherapeutic agents. There are now a number of effective natural and synthetic inhibitors with chemotherapy applications possessing antitumor activity ranging from oxidative stress induction to apoptosis. In this article, we first described the features and functions of the Trx system and then reviewed briefly its correlations with cancer. Finally, we summarized the present knowledge about the Trx/TrxR inhibitors as anticancer drugs.
硫氧还蛋白(Trx)、硫氧还蛋白还原酶(TrxR)和 NADPH 是参与氧化还原调节和抗氧化防御的 Trx 系统的关键成员。近年来,一些研究人员提供了有关 Trx 系统在癌症发展和进展中的作用的信息。这些报告表明,许多肿瘤细胞表达高水平的 Trx 和 TrxR,这可能导致肿瘤发生中的耐药性。因此,抑制 Trx 系统可能有助于癌症治疗和改善化疗药物。现在有许多有效的天然和合成抑制剂具有化疗应用,具有从氧化应激诱导到细胞凋亡的抗肿瘤活性。在本文中,我们首先描述了 Trx 系统的特征和功能,然后简要回顾了它与癌症的关系。最后,我们总结了作为抗癌药物的 Trx/TrxR 抑制剂的现有知识。